Cargando…
Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
BACKGROUND: Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study w...
Autores principales: | Wilson, C., Martin, C., Winter, M.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429539/ https://www.ncbi.nlm.nih.gov/pubmed/30937280 http://dx.doi.org/10.1016/j.jbo.2019.100226 |
Ejemplares similares
-
Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009) -
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021) -
Oral bisphosphonate compliance and persistence: a matter of choice?
por: Silverman, S. L., et al.
Publicado: (2010) -
Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
por: Park, Ji-Heh, et al.
Publicado: (2017) -
Long-Term Oral Bisphosphonate Compliance Focusing on Switching of Prescription Pattern
por: Ko, Kyung Rae, et al.
Publicado: (2020)